GlobeNewswire Inc | Jan 5, 2021 07:00AM EST

January 05, 2021

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Annexon) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced that a corporate update will be presented at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 4:30pm ET.

A live webcast of the event can be accessed under the Events & Presentations section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon, Inc.Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The companys pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to identify patients, and to measure target engagement and response to treatment. For more information, visitwww.annexonbio.com.

Investor Contacts:Jennifer Lew, Chief Financial OfficerAnnexon Biosciencesjlew@annexonbio.com

Sara Michelmoresmichelmore@macbiocom.com

Media Contacts:Miriam MasonAnnexon Biosciencesmmason@annexonbio.com

Caroline Rufo, Ph.D.crufo@macbiocom.com